Agilent Technologies to Sponsor USCAP 2016
Company to Share Latest Advances at Pathology Congress
SANTA CLARA, Calif., March 8, 2016
Agilent Technologies Inc. (NYSE: A) today announced that it will be a Silver sponsor of USCAP 2016, the annual gathering of the United States and Canadian Academy of Pathology, March 12-18, in Seattle.
The Agilent booth will showcase the company's portfolio of genomics and Dako pathology solutions. The company's Learning Theater, located next to its main booth in the Exhibition Hall, will feature international experts speaking on companion diagnostics, molecular pathology, next-generation sequencing and immunohistochemistry.
Agilent will also introduce a new white paper at USCAP: "Breast Cancer Diagnosis: Past, Present and Future," by pathologists Ping Tang and David G. Hicks of the University of Rochester in New York and Dr. Christine Desmedt of the Jules Bordet Institute in Brussels. The paper provides an overview of the use of immunohistochemistry in diagnosing and treating breast cancer.
"As a leader in companion diagnostics, we are proud to be a Silver sponsor of USCAP," said Jacob Thaysen, president of Agilent's Diagnostics and Genomics Group, which includes the Dako products for cancer diagnostics. "Our participation in the congress exemplifies our lasting commitment to education in pathology for better diagnoses and patient care."
About Agilent Technologies and Dako
Agilent Technologies Inc. (NYSE: A), a global leader in life sciences, diagnostics and applied chemical markets, is the premier laboratory partner for a better world. Agilent works with customers in more than 100 countries, providing instruments, software, services and consumables for the entire laboratory workflow. The company generated revenues of $4.04 billion in fiscal 2015 and employs about 12,000 people worldwide.
In 2012, Agilent acquired Dako, a well-known provider of reagents, instruments, software and expertise. Agilent's Dako pathology solutions help pathologists make accurate diagnoses and determine the most effective treatment for cancer patients.
# # #
+1 408 553 2005